Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (8729)	4/7/2001 11:07:23 AM
From: Biomaven	Read Replies (1) \| Respond to of 9719

I think Rick is correct that the Phase I/II terminology doesn't apply to this grant, which looks like a straight NIH grant to a researcher at an institution. Here's a little more on the SBIR-type grants from NIH: Small Business Innovation Research (SBIR) Program The SBIR program is a set-aside program designed to support innovative research conducted by small business concerns that has the potential for commercialization of the subject of the research. Innovation and the potential for commercialization are among the important factors included in the review criteria used in the scientific and technical merit evaluation process. The National Institutes of Health (NIH) welcomes grant applications from small businesses in any biomedical or behavioral research area as described in the solicitations below. Support under the Small Business Innovation Research (SBIR) program is normally provided for six months/$100,000 for Phase I and two years/$750,000 for Phase II. However, applicants may propose longer periods of time and greater amounts of funds necessary for completion of the project. In fiscal year (FY) 2000 (October 1, 1999-September 30, 2000), the NIH made SBIR grant and contract awards totaling $352 million. The amount available for the NIH SBIR program in FY 2001 is estimated to be $410 million, an increase of $58 million from the previous year. Note that the Senate has proposed sharply higher NIH funding, so funding from NIH may grow significantly. Peter

To: scaram(o)uche who wrote (8729)	4/10/2001 1:06:33 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 9719

Rick, As with you, the 500% factor of the growth of a tumor bothered me. Knowing that Dr. Tuszynski has a good reputation and MCP/Hahnemann University Hospital wasn't a new kid on the block, I decided to get a definitive answer to this "mystery" number. The following is the answer I got back from the company and it now makes sense...at least for the mouse model, as for human results I guess we will have to wait.. "The 560% reduction in growth means that tumors in control animals > receiving only saline grew 5.6 times larger than tumors in animals > receiving angiocidin treatment. Hope this answers your question. Thank > you for your interest in InKine.